Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 3, Pages 2623-2632Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c02010
Keywords
-
Categories
Funding
- Slovenian Research Agency [P1-0201, J1-1706]
Ask authors/readers for more resources
Scientists have developed a platform based on temperature-dependent aggregation data analysis, which can shorten the assessment of antibody stability and accelerate the optimization of antibody formulations. The strategy has shown accurate prediction of aggregate fractions for different therapeutic antibodies and has proved to be effective in the development and production of biological therapeutics.
Monoclonal antibodies are the fastest growing class of therapeutics. However, aggregation limits their shelf life and can lead to adverse immune responses. Assessment and optimization of the long-term antibody stability are therefore key challenges in the biologic drug development. Here, we present a platform based on the analysis of temperature-dependent aggregation data that can dramatically shorten the assessment of the long-term aggregation stability and thus accelerate the optimization of antibody formulations. For a set of antibodies used in the therapeutic areas from oncology to rheumatology and osteoporosis, we obtain an accurate prediction of aggregate fractions for up to three years using the data obtained on a much shorter time scale. Significantly, the strategy combining kinetic and thermodynamic analysis not only contributes to a better understanding of the molecular mechanisms of antibody aggregation but has already proven to be very effective in the development and production of biological therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available